On Monday shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) closed at $10.12. On March 19, it was reported that, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) announced that it has started patient enrolment in a phase II study on its investigational candidate NS2 for the treatment of Sjögren-Larsson syndrome. Apart from Sjögren-Larsson syndrome, the candidate is being developed for noninfectious anterior uveitis.
FibroGen, Inc. (NASDAQ:FGEN) in last trading activity advanced 5.83% to close at $31.59. Company weekly performance is 4.88% while its quarterly performance stands at 15.71%. FibroGen, Inc. (NASDAQ:FGEN) is -22.17% away from its 52 week high. FibroGen, Inc. (Nasdaq:FGEN) provided a corporate update and reported financial results for the year-ended December 31, 2014; Total operating expenses were $187.7 million, which includes $23.3 million of non-cash items.
On Monday shares of Apple Inc. (NASDAQ:AAPL) closed at $126.37. Company’s sales growth for last 5 years was 33.60% and EPS growth for next 5 years is recorded as 13.32%. Apple Inc. (NASDAQ:AAPL) is planning to unveil a new 4-inch Touch ID iPhone 6C at the end of the year, says reports. We’re receiving an initial look at the predicted smartphone, which features a somewhat new tweaked build and some additional tricks.
UTi Worldwide Inc. (NASDAQ:UTIW) has 0.20% insider ownership while its institutional ownership stands at 91.20%. In last trading activity company’s stock closed at $12.54. UTi Worldwide Inc. (NASDAQ:UTIW) announced that its fiscal 2015 fourth quarter conference call will be held on Tuesday, March 31, 2015 at 2:00 p.m. PDT (5:00 p.m. EDT) to review its financial results and answer questions.
On last trading day RPX Corporation (NASDAQ:RPXC) advanced 1.97% to close at $14.50. Its volatility for the week is 2.21% while volatility for the month is 2.27%. RPXC’s sales growth for past 5 years was 51.20% and its EPS growth for past 5 years was 6.77%. RPX Corporation (NASDAQ:RPXC) monthly performance is -0.55%.RPX Corp (NASDAQ:RPXC) was upgraded by analysts at TheStreet from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.